The EASL–EORTC guidelines do not currently recommend tumor biomarkers such as AFP, AFP-L3, and DCP for routine early HCC detection, as they lack cost-effectiveness and sufficient clinical efficacy [13]. This evidence concerns the gene AFP and neoplasm.